Skip to main content

Advertisement

SpringerLink
Log in

Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year

  • Kidney Diseases (G Ciancio, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

During the past half-decade, clinical trials have permitted major progress in treatment of metastatic renal cell carcinoma with the first generation of targeted therapies (bevacizumab, sunitinib, sorafenib, everolimus, and temsirolimus). New targeted agents such as axitinib, tivozanib, and dovitinib, all of which are tyrosine kinase inhibitors, have been developed in treatment of metastatic renal cell carcinoma. In the same time, more information regarding mechanism of disease and drug resistance shed light on new targets and new potent agents. We report an overview of the more relevant data published over the past year, which may modify the therapeutic landscape of kidney cancer in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011;16(2):45–50. This article is a review of the treatment of kidney cancer in 2011.

    Article  PubMed  Google Scholar 

  2. Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist. 2011;16(2):1–3.

    Article  PubMed  Google Scholar 

  3. •• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. This article reports the efficacy of a new tyrosine kinase inhibitor in a first-line setting of mRCC.

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol. 2011;29(suppl: LBA 308).

  5. •• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(suppl2):32–44. The author addresses the importance of prevention and treatment of adverse events of the targeted therapies to ensure efficacy.

    Article  PubMed  Google Scholar 

  6. Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 2010;11(6):571–8.

    Article  PubMed  CAS  Google Scholar 

  7. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360–3.

    Article  PubMed  CAS  Google Scholar 

  8. •• Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539–42. This article emphasizes that PBRM1 gene may be a major molecular abnormality on renal carcinoma.

    Article  PubMed  CAS  Google Scholar 

  9. • Suwaki N, Vanhecke E, Atkins KM, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med. 2011;3(85):85ra47. The authors report new potent targeted agents.

    Article  PubMed  Google Scholar 

  10. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9(6):1525–35.

    Article  PubMed  CAS  Google Scholar 

  11. Cho TP, Dong SY, Jun F, et al. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. J Med Chem. 2010;53(22):8140–9.

    Article  PubMed  Google Scholar 

  12. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507–16.

    Article  PubMed  CAS  Google Scholar 

  13. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

    Article  PubMed  CAS  Google Scholar 

  14. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol. 2007;8:975–84.

    Article  PubMed  Google Scholar 

  15. •• Rini B. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol. 2011;29 (suppl; abstr 4503). This article reports the superiority of axitinib compared to sorafenib in the second-line setting.

  16. Bhargava P, Esteves B, Al-Adhami M, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2010;28:15s(suppl: abstr 4599).

  17. Motzer RJ, Bhargava P, Esteves B, et al. A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2011;29(suppl 7; abstr 310).

  18. Angevin E, Lopez JA, Pande A, et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: a phase I/II dose finding and biomarker study. J Clin Oncol. 2009;15s (suppl; abstr 3563).

  19. • Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol. 2011;29(suppl; abstr 4551). This abstract reports the safety and promising efficacy of a new tyrosine kinase inhibitor in patients previously treated with VEGF inhibitors and/or mTOR Inhibitors.

  20. http://clinicaltrials.gov/ct2/show/NCT01223027

  21. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.

    Article  PubMed  CAS  Google Scholar 

  22. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon-alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  PubMed  CAS  Google Scholar 

  23. Logan T, McDermott D, Dutcher J, et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. J Clin Oncol. 2008;26(suppl; abstr 5050).

  24. Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60(4):684–90.

    Article  PubMed  Google Scholar 

  25. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.

    Article  PubMed  Google Scholar 

  26. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.

    Article  PubMed  CAS  Google Scholar 

  27. Richey SL, Culp SH, Jonasch E, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011;22(5):1048–53.

    Article  PubMed  CAS  Google Scholar 

  28. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22:1041–7.

    Article  PubMed  CAS  Google Scholar 

  29. •• Chapin BF, Delacroix SC, Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;60(5):964–71. This article suggests that surgery still remains safe after exposure to targeted therapy.

    Article  PubMed  Google Scholar 

  30. Escudier B. Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011;22:995–6.

    Article  PubMed  CAS  Google Scholar 

  31. http://clinicaltrials.gov/ct2/show/NCT00930033

  32. http://clinicaltrials.gov/ct2/show/NCT01099423

  33. Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol. 2010;28:295–301.

    Article  PubMed  Google Scholar 

  34. • Karam JA, Rini B, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439–44. This article underlines the importance of considering surgery even in the metastatic setting.

    Article  PubMed  Google Scholar 

  35. Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58:819–28.

    Article  PubMed  Google Scholar 

  36. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327–38.

    Article  PubMed  CAS  Google Scholar 

  37. National Cancer Institute Dictionary of Cancer Terms. http://www.cancer.gov/dictionary/;accessed

  38. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–50.

    Article  PubMed  CAS  Google Scholar 

  39. •• Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011;17(16):5443–50. The authors report a new prognostic model in the era of targeted therapy.

    Article  PubMed  Google Scholar 

  40. • Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma. Blessing or curse? Cancer. 2011;117:534–44. This article concludes that biologic hypothyroidism during treatment with sunitinib or sorafenib may be a predictive factor of response and a prognostic factor.

    Article  PubMed  Google Scholar 

  41. Rini B, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Canc Inst. 2011;103:763–73.

    Article  CAS  Google Scholar 

  42. • Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signalling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604. The authors report the prognostic role of hypertension (systolic or diastolic) during VEGF-R–inhibitor treatment.

    Article  CAS  Google Scholar 

  43. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011;16 suppl 2:14–22.

    Article  PubMed  Google Scholar 

  44. http://clinicaltrials.gov/ct2/show/NCT00631371

  45. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–81.

    Article  PubMed  Google Scholar 

Download references

Disclosures

M. Gross-Goupil: none; C. Massard: none. Pr. Alain Ravaud has served on boards for Novartis, Pfizer, Bayer, and GlaxoSmithKline; has received payment for the development of educational presentations from Roche and Pfizer; and has received travel expense compensation from Novartis, Pfizer, and GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Centre Hospitalo-Universitaire, Hôpital Saint André, 01 Rue Jean Burguet, 33075, Bordeaux, France

    Marine Gross-Goupil

  2. Department of Medical Oncology, SITEP, Gustave Roussy Institute, Villejuif, France

    Christophe Massard

  3. Bordeaux University Hospital, Hôpital Saint-André, Bordeaux, France

    Alain Ravaud

  4. Bordeaux University, Bordeaux, France

    Marine Gross-Goupil & Alain Ravaud

Authors
  1. Marine Gross-Goupil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Massard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alain Ravaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marine Gross-Goupil.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gross-Goupil, M., Massard, C. & Ravaud, A. Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year. Curr Urol Rep 13, 16–23 (2012). https://doi.org/10.1007/s11934-011-0232-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-011-0232-y

Keywords

Search

Navigation